Supplier News: Neuland Labs, Cambrex, Esteve CDMO, Samsung Biologics, Lonza & More
The latest from CDMOs, CMOs, and suppliers featuring Neuland Laboratories, Cambrex, Esteve CDMO, Samsung Biologics, Lonza, Adragos Pharma, Rois, Dalton Pharma Services, Codis, Forma Life Sciences, and West Pharmaceutical Services
Appointments
* Neuland Laboratories Names New CEO & Managing Director
Chemicals/Chemical API Manufacturing
* Cambrex Advances $120-M US API Mfg Expansion
* Esteve CDMO Begins Expansion of API Mfg Facility
Biologics Manufacturing
* Samsung Biologics Completes Acquisition of GSK Biomanufacturing Facility
Formulation Development/Drug Product Manufacturing
* Lonza Agrees To Divest Capsules & Health Ingredients Business
* Adragos Pharma Completes Acquisition of Sanofi Fill–Finish Facility in France
* Rovi’s Rois Completes Acquisition of BMS Injectables Facility in US
* Codis Expands Commercial Spray-Drying
* Forma Life Sciences Launches as New CDMO
Packaging
* West Pharmaceutical Services Expands Mfg for Injectable Drug Delivery Systems
Appointments
Neuland Laboratories Names New CEO & Managing Director
Neuland Laboratories, a CDMO of complex active pharmaceutical ingredients (APIs), has named Saharsh Davuluri as Chief Executive Officer (CEO) and Managing Director, effective immediately (as reported on April 1, 2026). He succeeds Sucheth Davuluri, formerly CEO and Managing Director, who now assumes the role of Executive Vice Chairman of the company.
Saharsh has been with the company for more than 18 years and will position the CDMO as a global API process development and commercial manufacturing specialist, which includes scale-up of complex APIs and peptides. The business has tripled its contract services revenues during the last three years, and he has led Neuland’s transformation into a new chemical entity-focused drug-substance CDMO.
Source: Neuland Laboratories
Chemicals/Chemical API Manufacturing
Cambrex Advances $120-M US API Mfg Expansion
Cambrex has completed initial engineering studies for a new, large-scale active pharmaceutical ingredient (API) manufacturing plant in Charles City, Iowa. This milestone marks progress toward the company’s previously announced $120-million investment in expanding its US API manufacturing capabilities. Groundbreaking for the new facility is scheduled to take place in late 2026.
The Charles City expansion will add a new plant with 140,000 liters of capacity, including large-scale and mid-scale reactors, advanced Hastelloy agitated filter dryers, and enhancements to existing manufacturing suites. Upon completion of this phase of expansion, the site will see a 20% increase in large-scale manufacturing capacity. This expansion is designed to support complex chemistry, including controlled substances, highly potent APIs, and commercial-scale liquid-phase peptide manufacturing.
In Europe, Cambrex continues to invest with a $30-million expansion underway at its Milan, Italy, site. The project will add new analytical development and process R&D capabilities as well as upgrades to multiple production plants. The Milan R&D expansion is expected to be completed in the second half of 2027, with additional land acquired to support future growth.
Source: Cambrex
Esteve CDMO Begins Expansion of API Mfg Facility
Esteve CDMO, part of Esteve, a Barcelona-based pharmaceutical company and CDMO, has commenced a $15.5-million investment to enhance production capabilities and associated space at its facility in Morton Grove, Illinois, which it acquired in July 2025.
Scheduled for completion in 2026, the work will see reactor upgrades to add powder-transfer systems and distillation tanks. Jacket insulation and a single thermal fluid circuit will be added to enhance thermal management and broaden the reactors’ operational temperature range to between -15°C and +140°C and simplify validation under GMP conditions.
Additionally, the site will implement cleanroom and ancillary equipment upgrades including a computer-based supervisory control and data acquisition (SCADA) system to monitor, control, and record manufacturing processes in real time, and installation of uninterruptible power supply systems that will help the operation of quality control laboratories.
Source: Esteve CDMO
Biologics Manufacturing
Samsung Biologics Completes Acquisition of GSK Biomanufacturing Facility
Samsung Biologics has completed its acquisition of a biomanufacturing facility in Rockville, Maryland, from GSK, establishing the company’s first manufacturing presence in the United States. The company had previously announced an agreement to acquire the facility in December 2025.
The Rockville site comprises two cGMP manufacturing plants with a combined 60,000 liters of drug-substance capacity, supporting both clinical and commercial biologics production across multiple manufacturing scales. With this addition, Samsung Biologics’ total global manufacturing capacity increases to 845,000 liters. The company also has 785,000 liters of capacity across its Bio Campus I and II in South Korea. In addition, the company has secured land for Bio Campus III, laying the groundwork for future capacity expansion to support next-generation therapies and emerging modalities.
Samsung Biologics will continue supplying the products previously manufactured at the site to GSK under the terms of the agreement, and the site will transition to serve additional contract manufacturing needs. Samsung Biologics says it also plans further investments to expand the site’s capacity and upgrade technologies.
Source: Samsung Biologics
Formulation Development/Drug Product Manufacturing
Lonza Agrees To Divest Capsules & Health Ingredients Business
In a strategic move to focus on being a pure-play CDMO, Lonza signed an agreement earlier this month (March 6, 2026) to divest its Capsules & Health Ingredients (CHI) business to Lone Star Funds, a private-equity firm, for an enterprise value of CHF 2.3 billion ($3 billion) at closing. The transaction is expected to close in the first half of 2026, subject to customary closing conditions relating to regulatory approvals and completion of the legal separation of CHI from Lonza’s wider business.
Upon closing, Lonza will receive upfront proceeds of CHF 1.7 billion ($2.2 billion) and retain a 40% stake in CHI, with an additional preferential participation in a future exit. Total undiscounted proceeds, including upfront and all future proceeds at full exit, are expected to be at or above CHF 3 billion (approximately $4 billion).
Lonza says it plans to invest the upfront proceeds into additional organic growth opportunities in line with its overall strategic plan, the One Lonza Strategy, a CDMO organic growth plan, as well as bolt-on acquisitions. The company says it will return CHF 500 million ($626 million) to shareholders through a share buyback following receipt of proceeds.
In addition, as part of its wider portfolio transformation, Lonza has also signed agreements to divest its Personalized Medicines business (the Cocoon Platform), the MODA software platform, and its small-molecules micronization site in Monteggio, Switzerland.
Source: Lonza
Adragos Pharma Completes Acquisition of Sanofi Fill–Finish Facility in France
Adragos Pharma, a Munich-Germany-based CDMO of drug products, has completed the acquisition of a commercial-scale sterile fill-finish facility in Maisons-Alfort, France, from Sanofi. The Maisons-Alfort site has industrial-scale capacity for prefilled syringes as well as liquid and lyophilized vials.
The site expands Adragos’ sterile injectables network by adding high-volume prefilled syringe manufacturing capabilities to its existing vial and ampoule filling operations in Jura, Switzerland, and Livron, France. Adragos operates manufacturing sites in France, Germany, Switzerland, and Japan as well as a development site in Greece.
Source: Adragos Pharma
Rovi’s Rois Completes Acquisition of BMS Injectables Facility in US
Rois, the CDMO arm of Laboratorios Farmacéuticos Rovi, a Madrid, Spain-based bio/pharmaceutical company, has closed on its acquisition from Bristol-Myers Squibb of an injectable drug-product manufacturing and packaging site in Phoenix, Arizona.
The approximate 370,000-square-foot facility includes a cytotoxic/high-potent (OEB5) area with commercial-scale lyophilization. Rois plans to install an Optima prefilled syringe (PFS) isolator line in a segregated non-potent area in 2027, which is projected to add approximately 65 million–70 million PFS capacity annually once operational. The US facility will be equipped for commercial-scale sterile fill-finish and packaging across vials, PFS, and cartridges.
With the acquisition of the Phoenix facility, Rois now has total global network capacity of over 800 million sterile units/year, which includes its production site in Madrid. The company has also entered into a toll manufacturing agreement with BMS at the Phoenix facility.
Source: Rois and Laboratorios Farmacéuticos Rovi
Dalton Pharma Services Expands Aseptic Powder Fill–Finish Capacity
Dalton Pharma Services, a CDMO of active pharmaceutical ingredients and drug products, reports the successful installation of a RoboFil aseptic powder fill-finish system at its facility in Toronto, Canada, to expand the company’s aseptic powder fill-finish capacity.
Source: Dalton Pharma Services
Codis Expands Commercial Spray-Drying
Codis, a recently launched CDMO specializing in commercial-scale spray drying, amorphous solid dispersions, and particle-engineering technologies, has announced an expansion of its UK manufacturing capabilities with the purchase of a GEA Pharma-SD type PSD-4 solvent-capable spray dryer.
The addition will take place at its 400,000 square-foot facility in Haverhill, UK. The PSD4 is a large-scale, cGMP pharmaceutical spray dryer designed to produce commercial batches up to 500 kg with a total capacity of 30,000 kg per year. The new facility will be operational in 2027.
This investment is supported by the UK government’s Life Sciences Innovative Manufacturing Fund (LSIMF), subject to final agreement of terms and conditions, which offers up to £520 million ($696 million) in capital grants to life science manufacturers to support economic growth and to build resilience for future health emergencies.
Source: Codis
Forma Life Sciences Launches as New CDMO
Forma Life Sciences has announced its launch as an independent, operator-owned CDMO focused on oral solid dosage formulation development, clinical manufacturing, and commercial drug-product manufacturing in the US. Forma Life Sciences was established following BioSelective Capital Investments’ acquisition of the US drug-product development and manufacturing operations of BioDuro, an Irvine, California-based CDMO. The transaction included two GMP facilities in Irvine, California focused on clinical and commercial oral solid dosage programs.
Forma operates two cGMP-compliant facilities in Irvine totaling more than 100,000 square feet and encompassing 27 GMP manufacturing suites. Both sites support:
- Oral solid dosage formulation development
- Clinical manufacturing for Phase I-III programs
- Process scale-up and technical transfer
- Commercial drug product manufacturing
The combined platform has the capacity to produce more than two billion tablet and capsule units annually.
Source: Forma Life Sciences
Packaging
West Pharmaceutical Services Expands Mfg for Injectable Drug Delivery Systems
West Pharmaceutical Services, a provider of products and services for injectable drug-delivery, has opened a new building at its current site in Damastown, Dublin, representing a 165,000-square-foot expansion, to support the company’s contract services and demand for customers’ high-volume treatments, including for diabetes and obesity. The expansion enhances West’s contract capabilities beyond its capabilities in component molding, device assembly, and packaging to now include advanced automation and expanded drug-handling capabilities at commercial scale.
Source: West Pharmaceutical Services
